Adult-onset growth hormone deficiency: Relation of postprandial dyslipidemia to premature atherosclerosis

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 6, 2003, Pages 2479-2488

  Twickler, T B ^a,b,c   Cramer, M J M ^b   Dallinga Thie, G M ^b   Chapman, M J ^a   Erkelens, D W ^b   Koppeschaar, H P F ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Internal Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; LIPID; SOMATOMEDIN BINDING PROTEIN;

ADIPOSE TISSUE; ADULT; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DYSLIPIDEMIA; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LIPID METABOLISM; MEAL; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0037630379     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030278     Document Type: Review

References (144)

1. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JCM 2000 Subclinical hypothroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 132:270-278
2. Becerra A, Bellido D, Luengo A, Piédrola G, De Luis DA 1999 Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin Nutr 18:319-322
3. Diekmann T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM 1998 Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 83:1752-1755
4. Perk M, O'Neil BJ 1997 The effect of thyroid hormone therapy on angiographic coronary artery disease progression. Can J Cardiol 13:273-276
5. Twickler ThB, Cramer MJM, Koppeschaar HPF, Vries WR de, Erkelens DW 2002 Cardiovascular endocrinology: a new dimension in medicine. Lancet 359:799
6. McGrath S, Morris M, Bouloux PM 1999 Growth hormone deficiency and atherosclerosis-is there a link? Growth Horm IGF Res 9:A9-A13
7. Bengtsson BA, Johansson G 1999 Effects of growth hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet 353:1898-1899
8. Saccà L 1997 GH deficiency and vascular disease: in search of the linking mechanism. Eur J Endocrinol 136:148-149
9. Steiner G 1993 Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 25:431-435
10. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR 1995 Postprandial state and atherosclerosis. Curr Opin Lipidol 6:286-290
11. Orme SM, McNally RJ, Carwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 38:2730-2734
12. Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E 1998 Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. Br Med J 316:1132-1133
13. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Bunger DB, Wareham NJ 2002 circulating concentrations of insulin-like growth factor I and development of glucose intolerance: a prospective observational study. Lancet 359:1740-1745
14. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T 2002 Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease; a population based case-control study. Circulation 106:939-944
15. Jenkins RC, Ross RJM 1998 Acquired growth hormone resistance in adults. Ballieres Clin Endocrinol Metabolism 12:315-329
16. Tisdale MJ 2001 Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6:164-174
17. Baxter RC 2000 Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol 278:E967-E976
18. Moschos SJ, Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317-332
19. Ferry Jr RJ, Cerri RW, Cohen P 1999 Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 51:53-67
20. Monzavi R, Cohen P 2002 IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab 16:433-447
21. Franklin SL, Ferry Jr RJ, Cohen P 2003 Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 88:900-907
22. Harrela M, Koistinen HA, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen J, Koistinen R, Seppala M 1996 Genetic and encironmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-I, and IGFBP-3. J Clin Invest 98:2612-2615
23. O'Sullivan DC, Szestak TA, Pell JM 2002 Regulation of IGF-I mRNA by GH: putative functions for class 1 and 2 message. Am J Physiol 283:E251-E258
24. Renaville R, Hammadi M, Portetelle D 2002 Role of the somatotropic axis in the mammalian metabolism. Dora Anim Endocrinol 23:351-360
25. Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801-831
26. Lassare C, Duron F, Binoux M 2001 Use of the ligand immunofunctional assay for human insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) to analyze IGFBP-3 lipolysis and IGF-I bioavailibility in healthy adults, GH-deficient and agromegalic patients, and diabetics. J Clin Endocrinol Metab 86:1942-1952
27. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
28. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B 2000 Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 85:1420-1425
29. Stewart PM, Sheppard MC 1999 Mortality and hypopituitarism. Growth Horm IGF Res 9 (Suppl):A15-A19
30. Kohno H, Ueyama N, Yanai S, Ukaji K, Honda S 1995 Beneficial effect of growth hormone on atherogenic risk in children with growth hormone deficiency. J Pediatr 126:953-955
31. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75-81
32. Bates AS, Bullivant B, Sheppard MC, Stewart PM 1999 Life expectancy following surgery for pituitary tumours. Clin Endocrinol (Oxf) 50:315-319
33. Tomlinson JW, Holden N, Hills RK, Wheatly K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431
34. Ross R 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809
35. Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ, Frenneaux MP, Rees A, Scanlon MF 2000 The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 142:254-262
36. Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF 1999 Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 50:457-464
37. Mombouli JV, VanHoutte PM 1999 Endothelial dysfunction: from physiology to therapy J Mol Cell Cardiol 31:61-74
38. Drexler H, Hornig B 1999 Endothelial dysfunction in human disease. J Mol Cell Cardiol 31:51-60
39. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Lüscher T, Rabelink T 1997 Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99:41-46
40. Boger RH 1998 Rote of nitric oxide in the haemodynamic effects of growth hormone. Growth Horm IGF Res 8:163-165
41. Boger RH, Skamira C, Bode-Böger SM, Brabant G, Muhlen Avz, Frohlich JC 1996 Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 98:2706-2713
42. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS 1994 Direct demonstration of insulin-like growth factor-1-induced nitric oxide production by endothelial cells. Kidney Int 45:598-604
43. Rosen T, Eden S, Larsson G, Wilhelmsen L, Bengtsson BA 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:195-200
44. Williams KJ, Tabas I 1995 The response-to-retention hypothesis of early atherogenesis. Arterioscter Thromb Vasc Biol 15:551-561
45. Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licino J, Tabas I 2000 Acute systemic inflammation upegulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 97:8681-8686
46. Erikstrup C, Pederson LM, Heickendorff L, Ledet T, Rasmussen LM 2001 Production of hyaluronan and chondroitin sulphate proteoglycans from human arterial smooth muscle: the effect of glucose, insulin, IGF-I or growth hormone. Eur J Endocrinol 145:193-198
47. Thogersen VB, Heickendorff L, Ledet T 1996 Effect of insulin and growth hormone on the synthesis of radiolabelled proteoglycans from cultured human arterial smooth-muscle cells. Eur J Endocrinol 134:326-330
48. Kamide K, Hori MT, Zhu JH, Takagawa Y, Barrett JD, Eggena P, Tuck ML 2000 Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 18:1051-1056
49. Chen Y, Capron L, Magnusson JO, Wallby LA, Arnqvist HJ 1998 Insulin-like growth factor-I stimulates vascular smooth muscle cell proliferation in rat aorta in vivo. Growth Horm IGF Res 8:299-303
50. Pfeiffer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN 1999 Growth hormone treatment revers early atherosclerotic changes in GH deficient adult. J Clin Endocrinol Metab 84:453-457
51. Bayes-Genis A, Conover CA, Schwartz RS 2000 The insulin-like growth factor axis. A review of atherosclerosis and restenosis. Circ Res 86:125-130
52. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT 1995 Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92:1758-1764
53. Furberg CD, Adams Jr HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA 1994 Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90:1679-1687
54. Forbat SM, Naoumova RP, Sidhu PS, Neuwirth C, MacMahon M, Thompson GR, Underwood SR 1998 The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimalthickness: a pilot study. J Cardiovasc Risk 5:1-10
55. Christ ER, Chowienczyk PJ, Sonksen PH, Russell-Jones DL 1999 Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin Endocrinol (Oxf) 51:21-25
56. Rudling M, Parini P, Angelin B 1999 Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Growth Horm IGF Res 9:A1-A7
57. Hew FL, O'Neal D, Kamarudin N, Alford FP, Best JD 1998 Growth hormone deficiency and cardiovascular risk. Ballieres Clin Endocrinol Metab 12:199216
58. Merimee TJ, Hollander W, Fineberg S 1972 Studies of hyperlipidemia in the human growth hormone deficient state. Metabolism 21:1053-1061
59. Merimee TJ, Pulkkinen A 1980 Familial combined hyperlipoproteinemia: evidence for a role of growth hormone deficiency in effecting its manifestation. J Clin Invest 65:829-835
60. de Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA 1994 Serum lipid levels in growth hormone-deficient men. Metab Clin Exp 43:199-203
61. Cuneo RC, Salomon F, Watts GF, Hesp R, Sonksen PH 1994 Growth hormone treatment improved serum tipids and lipoproteins in adults with growth hormone deficiency. Metabolism 12:1519-1523
62. Libber SM, Plotnick LP, Johanson AJ, Blizzard RM, Kwiterovich PO 1990 Long-term follow-up of hypopituitary patients treated with human growth hormone. Medicine 69:46-55
63. Salomon F, Cuneo RC, Hesp R, Sonksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797-1803
64. Binnerts A, Swart GR, Wilson JHP, Hoogerbrugge N, Pols HA, Birkenhäger JC, Lamberts SW 1992 The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 37:79-87
65. Stiegler C, Leb G 2003 One year of replacement therapy with growth hormone deficiency. Endocrinol Metab Clin North Am 1:A37-A42
66. Russell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR, Sönksen PH 1994 The effect of growth hormone replacement on serum lipids, lipoprotems, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol (Oxf) 41:345-350
67. Gleeson HK, Souza AH, Gill MS, Wieringa GE, Barretto ES, Barretto-Filho JA, Shaket SM, Auilar-Oliveira MH, Clayton PE 2002 Lipid profiles in untreated severe congenital isolated growth hormone deficiency through the lifespan. Clin Endocrinol (Oxf) 57:89-95
68. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA 1993 Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 13:296-301
69. Whitehead HM, Boreham C, McIllrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled crossover study. Clin Endocrinol (Oxf) 36:45-52
70. Degerblad M, Elgindy N, Hall K, Sjoberg HE, Thoren M 2003 Potent effect of recombinant human growth hormone on bone mineral density and body composition in adults with panhypopituitarism Acta Endocrinol (Copenh) 126:387-393
71. Modigliani E, Kerchouni R, Uzzan B, Valensi P, Chanson P, Caron J 1994 Modification of blood lipids and lipoproteins after human growth hormone treatment in adults with growth hormone deficiency: a preliminary report. Endocrinol Metab Clin North Am 1:A31-A35
72. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston DG 2000 Effects of 7 year of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85:3762-3769
73. Christ ER, Wierzbicki AS, Cummings MH, Umpleby AM, Russell-Jones DL 1999 Dynamics of lipoprotem metabolism in adult growth hormone deficiency. J Endocrinol Invest 22:S16-S21
74. Murray RD, Wieringa GE, Lissett CA, Darzy KH, Smethurst LE, Shalet SM 2002 Low dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol (Oxf) 56:525-532
75. Miller M 1999 The epidemiology of triglyceride as a coronary artery disease risk factor Clin Cardiol 22:SII-1-SII-6
76. Karpe F 1999 Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 246:341-355
77. Karpe F, Boquist S, Tang R, Bond GM, De Faire U, Hamsten A 2001 Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21
78. Gianturco SH, Bradley WA 1999 Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin Cardiol 22:SII-7-SII-14
79. Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, De Faire U, Karpe F, Hamsten A 1999 Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middleaged men. Circulation 100:723-728
80. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A 1996 Clearance of chylomicron remnants in normolipidemic patients with coronary, artery disease: case control study over three years. Br Med J 312:936-939
81. Kearney T, De Gallegos CN, Chrisoulidou A, Gray R, Bannister P, Venkatesan S, Johnston DG 2001 Hypopituitarsim is associated with triglyceride enrichment of very low-density lipoprotein. J Clin Endocrinol Metab 86:3900-3906
82. O'Neal D, Hew F, Sikaris K, Ward G, Alford F, Best JD 1996 Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy. J Clin Endocrinol Metab 81:2448-2454
83. Zilversmit DB 1979 Atherogenesis: a postprandial phenomenon. Circulation 60:473-485
84. Sharrett AR, Heiss G, Chambless LE, Boerwinkle E, Coady SA, Folsom AR, Patsch W 2001 Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21:275-281
85. Noutsou M, Georgopoulos A 1999 Effects of simvastatin on fasting and postprandial triglyceride-rich lipoproteins in patients with type I diabetes mellitus. J Diabet Compl 13:98-104
86. Twickler TB, Dallinga-Thie GM, Valk HW de, Schreuder PCNJ, Jansen H, Castro Cabezas M, Erkelens DW 2000 High dose of simvastatine normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:2422-2427
87. Packard CJ 1999 Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. Curr Opin Lipidol 10:237-244
88. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasuhramaniam S, Baron O, Branson J, Morgan J 1987 Chylomicrons and chylomicron remnants in coronary artery disease: a case control study. Atherosclerosis 65:181-185
89. Karpe F, De Faire U, Mercuri M, Bond MG, Hellenius ML, Hamsten A 1998 Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 141:307-314
90. Cohn JS, Marcoux C, Davignon J 1999 Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19:2474-2486
91. Doi H, Kugiyama K, Sugiyama S, Ogata N, Kolde SI, Nakamura S, Yasue H 2000 Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through e redox-sensitive mechanism. Circulation 102:670676
92. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H 1998 Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526
93. Wilmink HW, Twickler ThB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, Rabelink TJ, Stroes E 2001 Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res 50:577-582
94. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y, Oka H, Ogata N, Hirata A, Yamamoto Y, Yasue H 1999 Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation. Arterioscler Thromb Vasc Biol 19:1918-1924
95. Al-Shoumer KA, Cox KH, Hughes CL, Richmond W, Johnston DG 1997 Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy. J Clin Endocrinol Metab 82:26532659
96. Twickler TB, Wilmink HW, Schreuder PCNJ, Cabezas MC, Van Dam PS, Koppeschaar HPF, Erkelens DW, Dallinga-Thie GM 2000 Growth hormone (GH) treatment decreases postprandial remnant-like particle cholesterol concentration and improves endothelial function in adult-onset GH deficiency. J Clin Endocrinol Metab 85:4683-4689
97. Oscarsson J, Ottosson M, Eden S 1999 Effects of growth hormone on lipoprotein lipase and hepatic lipase. J Endocrinol Invest 22:S2-S9
98. Tanaka A, Ai M, Kobayashi Y, Tamura M, Shimokado K, Numano F 2001 Metabolism of triglyceride-rich lipoproteins and their role in atherosclerosis. Ann NY Acad Sci 947:207-212
99. Beisiegel U 1995 Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. Curr Opin Lipidol 6:117-122
100. Rudling M, Norstedt G, Olivecrona H, Reiner E, Gustafsson JA, Angelin B 1992 Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 89:6983-6987
101. Rudling M, Angelin B 2001 Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J 15:1350-1356
102. Twickler TB, Prinsen HC, Vries WR de, Koppeschaar HPF, Sain-van der Velden MG 2002 Analysis of the separate secretion of very-low-density lipoprotein (VLDL)-1 and VLDL-2 by the liver will be a principal factor in resolving the proatherogenic lipoprotein profile in hypopituitarism. J Clin Endocrinol Metab 87:1907
103. Assmann G, Schulte H, Von Eckardstein A, Huang YD 1996 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124:S11-S20
104. Beentjes JAM, Tol Av, Sluiter WJ, Dullaart RP 2000 Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153:491-498
105. Beentjes JAM, Van Tol A, Sluiter WJ, Dullaart RPF 2000 Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scand J Clin Lab Invest 60:189-198
106. Tall AR, Jiang XC, Luo Y, Silver D 2000 1999 George Lyman Duff Memorial Lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 20:1185-1188
107. Beentjes JAM, Van Tol A, Sluiter WJ, Dullaart RPF 2000 Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. J Lipid Res 41:925-932
108. Rader DJ, Dugi KA 2000 The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost 26:521-528
109. Yu KC, Cooper AD 2001 Postprandial lipoproteins and atherosclerosis. Front Biosci 6:D332-D354
110. Kugiyama K, Motoyama T, Doi H, Kawano H, Hirai N, Soejima H, Miyao H, Takazoe K, Moriyama Y, Mizuno Y, Tsunoda R, Ogawa H, Sakamoto T, Sugiyama S, Yasue H 1999 Improvement of endothelial vasomotor dysfunction by treatment with alpha tocopherol in patients with high remnant lipoprotein levels. J Am Coll Cardiol 33:1512-1518
111. Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M 2002 Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 91:263-271
112. Kowala MC, Recce R, Beyer S, Gu C, Valentine M 2000 Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 149:323-330
113. Proctor SD, Pabla CK, Mamo JCL 2000 Arterial intimal retention of proatherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 149:315-322
114. Gottsater A, Forsblad J, Matzsch T, Persson K, Ljungcrantz I, Ohlsson K, Lindgarde F 2002 Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. J Intern Med 251:61-68
115. Boyajian RA, Otis SM 2002 Atherogenic progression of carotid stenosis associates selectively with monocyte fraction in circulating leukocytes. Eur J Neurol 9:307-310
116. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J 2002 Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750-754
117. Twickler TB, Visseren FLJ, Dallinga-Thie GM 2000 Pro-inflammatory response induced through intestinal derived small triglyceride-rich particles (TRP) in adult-onset growth hormone deficiency (AGHD). Atherosderosis 151:S-11.
118. van Lenten BJ, Fogelman AM, Jackson RL, Shapiro S, Haberland ME, Edwards PA 1995 Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded monocytes-macrophages. J Biol Chem 260:8783-8788
119. Wabitsch M, Heinze E, Hauner H, Shymko RM, Teller WM, de Meyts P, Ilondo MM 1996 Biological effects of human growth hormone in rat adipocyte precursor cells and newly differentiated adipocytes in primary culture. Metabolism 45:34-42
120. Gerver WJ, De Bruin R, Waal HA, Aldewereld B, Theunissen P, Westerterp KR 2000 Effects of discontinuation of growth hormone treatment on body composition and metabolism. Horm Res 53:215-220
121. Carrel AL, Allen DB 2000 Effects of growth hormone on body composition and bone metabolism. Endocrine 12:163-172
122. Jones PH 2000 Diet and pharmacologic therapy of obesity to modify atherosclerosis. Curr Atheroscler Rep 2:314-320
123. Despres JP 1998 The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res 6(Suppl 1):8S-17S
124. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood G, Monson JP 1998 The effect of growth hormone replacement therapy on cortisolcortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11-β-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) 48:153-162
125. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP 1999 The differential effect of food intake and β-adrenergic stimulation on adiposederived hormones and cytokines in man. J Clin Endocrinol Metab 84:21262133
126. Fried SK, Bunkin DA, Greenberg AS 1998 Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850
127. Snel YEM, Doerga ME, Brummer RJM, Zelissen PMJ, Koppeschaar HPF 1995 Magnetic resonance imaging-assessed adipose tissue and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Arterioscler Thromb Vasc Biol 15:1543-1548
128. Cases JA, Barzilai N 2000 The regulation of body fat distribution and the modulation of insulin action. Int J Obes 24:S63-S66
129. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
130. Lente F van 2000 Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 293:31-52.
131. Kullo IJ, Gau GT, Tajik AJ 2000 Novel risk factors for atherosclerosis. Mayo Clin Proc 75:369-380
132. Hotamisligil GS 2000 Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes 24:S23-S27
133. Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278
134. Karpe F 2002 Adipose tissue is a primary source of generation of remnant lipoproteins. The missed link between obesity and atherosclerosis. Circulation 106:II-44
135. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE 2003 Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157:25-31
136. Janssen JA, Lamberts SW 1999 Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis? J Endocrinol Invest 22:313-315
137. Daughaday WH, Rotwein P 1989 Insulin-like growth factors I and II, peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 10:68-91
138. Pagter-Holthuizen P, van Schaik FM, Verduijn GM, van Ommen GJ, Bouma BN, Jansen M, Sussenbach JS 1986 Organization of the human genes for insulin-like growth factors I and II. FEBS Lett 195:179-184
139. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudsin T, Stampfer M, Pollak M 2001 Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274-1280
140. Estivariz CF, Ziegler TR 1997 Nutrition and the insulin-like growth factor system. Endocrine 7:65-71
141. Noel M, Chevenne D, Porquet D 2001 Utility of insulin-like growth factor-I and its binding protein assays. Curr Opin Clin Nutr Metab Care 4:399-405
142. Carroll PV, Van den Berghe G 2001 Safety aspects of pharmacological GH therapy in adults. Growth Horm IGF Res 11:166-172
143. Janssen JA, Lamberts SW 2002 The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 146:467-477
144. Kerkhof P van, Strous GJ 2001 The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem Soc Trans 29:488-493